NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
NASDAQ:NUTX • US67079U3068
106.77 USD
+5.44 (+5.37%)
Last: Feb 18, 2026, 11:55 AM
Overall NUTX gets a fundamental rating of 7 out of 10. We evaluated NUTX against 102 industry peers in the Health Care Providers & Services industry. NUTX has an excellent financial health rating, but there are some minor concerns on its profitability. NUTX is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make NUTX a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
- NUTX had positive earnings in the past year.
- NUTX had a positive operating cash flow in the past year.
- In the past 5 years NUTX reported 4 times negative net income.
- In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
- NUTX has a Return On Assets of 11.83%. This is amongst the best in the industry. NUTX outperforms 96.08% of its industry peers.
- The Return On Equity of NUTX (35.96%) is better than 94.12% of its industry peers.
- NUTX has a better Return On Invested Capital (38.79%) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.83% | ||
| ROE | 35.96% | ||
| ROIC | 38.79% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of NUTX (11.63%) is better than 97.06% of its industry peers.
- NUTX has a better Operating Margin (35.72%) than 99.02% of its industry peers.
- With a decent Gross Margin value of 55.01%, NUTX is doing good in the industry, outperforming 78.43% of the companies in the same industry.
- In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.72% | ||
| PM (TTM) | 11.63% | ||
| GM | 55.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
- NUTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for NUTX has been increased compared to 1 year ago.
- Compared to 5 years ago, NUTX has more shares outstanding
- Compared to 1 year ago, NUTX has an improved debt to assets ratio.
2.2 Solvency
- NUTX has an Altman-Z score of 2.95. This is not the best score and indicates that NUTX is in the grey zone with still only limited risk for bankruptcy at the moment.
- NUTX has a Altman-Z score of 2.95. This is in the better half of the industry: NUTX outperforms 62.75% of its industry peers.
- The Debt to FCF ratio of NUTX is 1.87, which is an excellent value as it means it would take NUTX, only 1.87 years of fcf income to pay off all of its debts.
- NUTX has a Debt to FCF ratio of 1.87. This is amongst the best in the industry. NUTX outperforms 81.37% of its industry peers.
- A Debt/Equity ratio of 0.95 indicates that NUTX is somewhat dependend on debt financing.
- The Debt to Equity ratio of NUTX (0.95) is comparable to the rest of the industry.
- Although NUTX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 2.95 |
ROIC/WACC5.23
WACC7.41%
2.3 Liquidity
- NUTX has a Current Ratio of 3.20. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.20, NUTX belongs to the top of the industry, outperforming 84.31% of the companies in the same industry.
- A Quick Ratio of 3.18 indicates that NUTX has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.18, NUTX belongs to the top of the industry, outperforming 85.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.18 |
3. Growth
3.1 Past
- NUTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 873.64%, which is quite impressive.
- NUTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 236.03%.
- The Revenue has been growing by 222.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)873.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%551.16%
Revenue 1Y (TTM)236.03%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%239.87%
3.2 Future
- Based on estimates for the next years, NUTX will show a very strong growth in Earnings Per Share. The EPS will grow by 44.72% on average per year.
- The Revenue is expected to grow by 51.11% on average over the next years. This is a very strong growth
EPS Next Y78.24%
EPS Next 2Y56.64%
EPS Next 3Y44.72%
EPS Next 5YN/A
Revenue Next Year223.7%
Revenue Next 2Y83.21%
Revenue Next 3Y51.11%
Revenue Next 5YN/A
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 5.77 indicates a rather cheap valuation of NUTX.
- 97.06% of the companies in the same industry are more expensive than NUTX, based on the Price/Earnings ratio.
- NUTX is valuated cheaply when we compare the Price/Earnings ratio to 27.16, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 4.98, which indicates a rather cheap valuation of NUTX.
- Based on the Price/Forward Earnings ratio, NUTX is valued cheaper than 99.02% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.10, NUTX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.77 | ||
| Fwd PE | 4.98 |
4.2 Price Multiples
- NUTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NUTX is cheaper than 98.04% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 97.06% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.33 | ||
| EV/EBITDA | 2.35 |
4.3 Compensation for Growth
- NUTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- NUTX has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as NUTX's earnings are expected to grow with 44.72% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y56.64%
EPS Next 3Y44.72%
5. Dividend
5.1 Amount
- No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:NUTX (2/18/2026, 11:55:54 AM)
106.77
+5.44 (+5.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-19 2025-11-19/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners35.1%
Inst Owner Change-1.45%
Ins Owners2.39%
Ins Owner Change0%
Market Cap754.86M
Revenue(TTM)981.20M
Net Income(TTM)114.07M
Analysts82.22
Price Target255 (138.83%)
Short Float %16.69%
Short Ratio4.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend1.28
Dividend Growth(5Y)N/A
DP39.41%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)298.6%
Min EPS beat(2)-0.77%
Max EPS beat(2)597.97%
EPS beat(4)3
Avg EPS beat(4)2386.61%
Min EPS beat(4)-0.77%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.29%
Min Revenue beat(2)7.78%
Max Revenue beat(2)22.8%
Revenue beat(4)4
Avg Revenue beat(4)79.58%
Min Revenue beat(4)7.78%
Max Revenue beat(4)211.33%
Revenue beat(8)7
Avg Revenue beat(8)41.36%
Revenue beat(12)8
Avg Revenue beat(12)27.1%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43.7%
EPS NY rev (1m)0%
EPS NY rev (3m)352.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.77 | ||
| Fwd PE | 4.98 | ||
| P/S | 0.77 | ||
| P/FCF | 4.33 | ||
| P/OCF | 4.25 | ||
| P/B | 2.38 | ||
| P/tB | 2.68 | ||
| EV/EBITDA | 2.35 |
EPS(TTM)18.49
EY17.32%
EPS(NY)21.42
Fwd EY20.06%
FCF(TTM)24.65
FCFY23.09%
OCF(TTM)25.15
OCFY23.55%
SpS138.78
BVpS44.86
TBVpS39.84
PEG (NY)0.07
PEG (5Y)N/A
Graham Number136.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.83% | ||
| ROE | 35.96% | ||
| ROCE | 44.98% | ||
| ROIC | 38.79% | ||
| ROICexc | 49.2% | ||
| ROICexgc | 52.2% | ||
| OM | 35.72% | ||
| PM (TTM) | 11.63% | ||
| GM | 55.01% | ||
| FCFM | 17.76% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 17% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 117.8 | ||
| Cash Conversion | 47.91% | ||
| Profit Quality | 152.79% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.18 | ||
| Altman-Z | 2.95 |
F-Score8
WACC7.41%
ROIC/WACC5.23
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)873.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%551.16%
EPS Next Y78.24%
EPS Next 2Y56.64%
EPS Next 3Y44.72%
EPS Next 5YN/A
Revenue 1Y (TTM)236.03%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%239.87%
Revenue Next Year223.7%
Revenue Next 2Y83.21%
Revenue Next 3Y51.11%
Revenue Next 5YN/A
EBIT growth 1Y1170.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1313.93%
EBIT Next 3Y163.37%
EBIT Next 5YN/A
FCF growth 1Y3319.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2258.27%
OCF growth 3YN/A
OCF growth 5YN/A
NUTEX HEALTH INC / NUTX FAQ
What is the ChartMill fundamental rating of NUTEX HEALTH INC (NUTX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to NUTX.
Can you provide the valuation status for NUTEX HEALTH INC?
ChartMill assigns a valuation rating of 10 / 10 to NUTEX HEALTH INC (NUTX). This can be considered as Undervalued.
What is the profitability of NUTX stock?
NUTEX HEALTH INC (NUTX) has a profitability rating of 6 / 10.
What is the expected EPS growth for NUTEX HEALTH INC (NUTX) stock?
The Earnings per Share (EPS) of NUTEX HEALTH INC (NUTX) is expected to grow by 78.24% in the next year.
How sustainable is the dividend of NUTEX HEALTH INC (NUTX) stock?
The dividend rating of NUTEX HEALTH INC (NUTX) is 0 / 10 and the dividend payout ratio is 39.41%.